Log in

Relevant bibliographies by topics / Iron Complexes - Anticancer Agents / Journal articles

To see the other types of publications on this topic, follow the link: Iron Complexes - Anticancer Agents.

Journal articles on the topic 'Iron Complexes - Anticancer Agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Iron Complexes - Anticancer Agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wani, Waseem A., Umair Baig, Sheikh Shreaz, et al. "Recent advances in iron complexes as potential anticancer agents." New Journal of Chemistry 40, no. 2 (2016): 1063–90. http://dx.doi.org/10.1039/c5nj01449b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Matos, Cristina P., Yasemin Yildizhan, Zelal Adiguzel, et al. "New ternary iron(iii) aminobisphenolate hydroxyquinoline complexes as potential therapeutic agents." Dalton Transactions 48, no. 24 (2019): 8702–16. http://dx.doi.org/10.1039/c9dt01193e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kongot, Manasa, Dinesh S. Reddy, Vishal Singh, Rajan Patel, Nitin Kumar Singhal, and Amit Kumar. "ONS donor entwined iron(iii) and cobalt(iii) complexes with exemplary safety profile as potent anticancer and glucose uptake agents." New Journal of Chemistry 43, no. 27 (2019): 10932–47. http://dx.doi.org/10.1039/c9nj00883g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wani, Waseem A., Umair Baig, Sheikh Shreaz, et al. "ChemInform Abstract: Recent Advances in Iron Complexes as Potential Anticancer Agents." ChemInform 47, no. 13 (2016): no. http://dx.doi.org/10.1002/chin.201613218.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Poursharifi, Mina, Marek T. Wlodarczyk, and Aneta J. Mieszawska. "Nano-Based Systems and Biomacromolecules as Carriers for Metallodrugs in Anticancer Therapy." Inorganics 7, no. 1 (2018): 2. http://dx.doi.org/10.3390/inorganics7010002.

Full text

Abstract:

Since the discovery of cisplatin and its potency in anticancer therapy, the development of metallodrugs has been an active area of research. The large choice of transition metals, oxidation states, coordinating ligands, and different geometries, allows for the design of metal-based agents with unique mechanisms of action. Many metallodrugs, such as titanium, ruthenium, gallium, tin, gold, and copper-based complexes have been found to have anticancer activities. However, biological application of these agents necessitates aqueous solubility and low systemic toxicity. This minireview highlights the emerging strategies to facilitate the in vivo application of metallodrugs, aimed at enhancing their solubility and bioavailability, as well as improving their delivery to tumor tissues. The focus is on encapsulating the metal-based complexes into nanocarriers or coupling to biomacromolecules, generating efficacious anticancer therapies. The delivery systems for complexes of platinum, ruthenium, copper, and iron are discussed with most recent examples.

APA, Harvard, Vancouver, ISO, and other styles

6

Matos, Cristina P., Zelal Adiguzel, Yasemin Yildizhan, et al. "May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?" European Journal of Medicinal Chemistry 176 (August 2019): 492–512. http://dx.doi.org/10.1016/j.ejmech.2019.04.070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lenis-Rojas, Oscar A., Sandra Cordeiro, Marta Horta-Meireles, et al. "N-Heterocyclic Carbene Iron Complexes as Anticancer Agents: In Vitro and In Vivo Biological Studies." Molecules 26, no. 18 (2021): 5535. http://dx.doi.org/10.3390/molecules26185535.

Full text

Abstract:

Cisplatin and its derivatives are commonly used in chemotherapeutic treatments of cancer, even though they suffer from many toxic side effects. The problems that emerge from the use of these metal compounds led to the search for new complexes capable to overcome the toxic side effects. Here, we report the evaluation of the antiproliferative activity of Fe(II) cyclopentadienyl complexes bearing n-heterocyclic carbene ligands in tumour cells and their in vivo toxicological profile. The in vitro antiproliferative assays demonstrated that complex Fe1 displays the highest cytotoxic activity both in human colorectal carcinoma cells (HCT116) and ovarian carcinoma cells (A2780) with IC50 values in the low micromolar range. The antiproliferative effect of Fe1 was even higher than cisplatin. Interestingly, Fe1 showed low in vivo toxicity, and in vivo analyses of Fe1 and Fe2 compounds using colorectal HCT116 zebrafish xenograft showed that both reduce the proliferation of human HCT116 colorectal cancer cells in vivo.

APA, Harvard, Vancouver, ISO, and other styles

8

Pape, Veronika F. S., Anikó Gaál, István Szatmári, et al. "Relation of Metal-Binding Property and Selective Toxicity of 8-Hydroxyquinoline Derived Mannich Bases Targeting Multidrug Resistant Cancer Cells." Cancers 13, no. 1 (2021): 154. http://dx.doi.org/10.3390/cancers13010154.

Full text

Abstract:

Resistance to chemotherapeutic agents is a major obstacle in cancer treatment. A recently proposed strategy is to target the collateral sensitivity of multidrug resistant (MDR) cancer. Paradoxically, the toxicity of certain metal chelating agents is increased, rather than decreased, by the function of P-glycoprotein (Pgp), which is known to confer resistance by effluxing chemotherapeutic compounds from cancer cells. We have recently characterized and compared the solution’s chemical properties including ligand protonation and the metal binding properties of a set of structurally related 8-hydroxyquinoline derived Mannich bases. Here we characterize the impact of the solution stability and redox activity of their iron(III) and copper(II) complexes on MDR-selective toxicity. Our results show that the MDR-selective anticancer activity of the studied 8-hydroxyquinoline derived Mannich bases is associated with the iron deprivation of MDR cells and the preferential formation of redox-active copper(II) complexes, which undergo intracellular redox-cycling to induce oxidative stress.

APA, Harvard, Vancouver, ISO, and other styles

9

Maloň, Michal, Zdeněk Trávnı́ček, Miroslav Maryško, et al. "Metal complexes as anticancer agents 2. Iron(III) and copper(II) bio-active complexes with N6-benzylaminopurine derivatives." Inorganica Chimica Acta 323, no. 1-2 (2001): 119–29. http://dx.doi.org/10.1016/s0020-1693(01)00611-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Al-Shboul, Tareq M. A., Mohammad El-khateeb, Zaid H. Obeidat, et al. "Synthesis, Characterization, Computational and Biological Activity of Some Schiff Bases and Their Fe, Cu and Zn Complexes." Inorganics 10, no. 8 (2022): 112. http://dx.doi.org/10.3390/inorganics10080112.

Full text

Abstract:

Four new symmetrical Schiff bases derived from 2,2′-diamino-6,6′-dibromo-4,4′-dimethyl-1,1′-biphenyl or 2,2′-diamino-4,4′-dimethyl-1,1′-biphenyl, and 3,5-dichloro- or 5-nitro-salicylaldehyde, were synthesized and reacted with copper-, iron- and zinc-acetate, producing the corresponding complexes. The Schiff bases and their metal complexes were characterized by 1H-, 13C-NMR, IR and UV-Vis spectroscopy and elemental analysis. The structures of one Schiff base and the two zinc complexes were resolved by X-ray structure determination. Density functional theory (DFT) calculations at the B3LYP/6-31G(d) level of the latter compounds were carried out to optimize and examine their molecular geometries. The biomedical applications of the Schiff bases and their complexes were investigated as anticancer or antimicrobial agents.

APA, Harvard, Vancouver, ISO, and other styles

11

Selyutina, Olga Yu, Simon V. Babenko, Irina A. Slepneva, Nikolay E. Polyakov, and George J. Kontoghiorghes. "Increased Free Radical Generation during the Interaction of a Quinone-Quinoline Chelator with Metal Ions and the Enhancing Effect of Light." Pharmaceuticals 16, no. 8 (2023): 1116. http://dx.doi.org/10.3390/ph16081116.

Full text

Abstract:

Schiff bases and similar molecules forming metal complexes may cause redox effects, which may also be influenced by light. Anthraquinones such as doxorubicin and idarubicin are widely used antitumor agents, which can generate reactive oxygen species (ROS), stimulated by both the presence of iron and copper ions and also by light. The generated ROS can cause DNA scission, cell membrane oxidation, and many other toxic effects. The redox activity of the quinone-quinoline chelator 2-phenyl-4-(butylamino)naphtho [2,3-h]quinoline-7,12-dione (Q1) was investigated in the presence of iron, copper, and zinc. The influence of light in these interactions was also examined. The chemically induced dynamic nuclear polarization (CIDNP), nuclear magnetic resonance (NMR), and electron paramagnetic resonance (EPR) methods were used to elucidate the molecular changes and ROS generation effects of the Q1 metal interactions. A model electron transfer reaction system between 1,4-dihydropyridine and Q1 was utilized to demonstrate that the chelate complexes of Q1 with both Fe(III) and Cu(II) ions were more redox active than Q1 itself. Similarly, CIDNP and NMR data showed that the concentration dependence of the free radicals yield is much higher in the presence of Fe(III) and Cu(II) ions, in comparison to Zn(II), and also that it increased in the presence of light. These findings underline the role of transition metal ions and Q1 in cyclic redox chain reactions and increase the prospect of the development of copper- and iron-based chelating agents, including Q1 and its derivatives, for anticancer therapy. Furthermore, these findings also signify the effect of light on enhancing ROS formation by Q1 and the prospect of utilizing such information for designing target specific anticancer drugs for photodynamic therapy.

APA, Harvard, Vancouver, ISO, and other styles

12

Ivanova, Stefka, Stefan Balkanski, Petar Atanasov, et al. "Antitumor and antioxidant activity of some metal complex compounds." Pharmacia 70, no. 2 (2023): 375–82. http://dx.doi.org/10.3897/pharmacia.70.e105845.

Full text

Abstract:

In the last few years, interest in platinum drugs has increased. Successful treatment depends to a large extent on complex therapy and early diagnosis, which determines the great importance of knowledge of risk groups, clinical symptoms, and targeted use of diagnostic methods with biomarkers, biopsy and diagnostic imaging for early detection of the malignant process. Today, the mono-target strategy is being replaced by a poly-target therapy strategy, which achieves greater clinical efficacy in tumors with defined biomarkers. Key developments include elucidation of the mechanisms of tumor resistance to these drugs, the introduction of some new platinum- based agents and clinical combination studies using platinum drugs with resistance modulators or new drug-targeted drugs. Improved delivery of platinum drugs to tumors has been studied in early clinical trials using liposomal or copolymer-based products. Other investigated as anticancer agents are ruthenium and iron complexes. Ln(III) complexes have been shown to exert antioxidant activity.

APA, Harvard, Vancouver, ISO, and other styles

13

Bal-Demirci, Tülay, Gulsah Congur, Arzum Erdem, et al. "Iron(iii) and nickel(ii) complexes as potential anticancer agents: synthesis, physicochemical and structural properties, cytotoxic activity and DNA interactions." New Journal of Chemistry 39, no. 7 (2015): 5643–53. http://dx.doi.org/10.1039/c5nj00594a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Pilon, Adhan, Julia Lorenzo, Sergi Rodriguez‐Calado, et al. "New Cyclams and Their Copper(II) and Iron(III) Complexes: Synthesis and Potential Application as Anticancer Agents." ChemMedChem 14, no. 7 (2019): 770–78. http://dx.doi.org/10.1002/cmdc.201800702.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Mohamad, Ahmad Desoky M., M. J. A. Abualreish, and Ahmed M. Abu-Dief. "Temperature and salt effects of the kinetic reactions of substituted 2-pyridylmethylene-8-quinolyl iron (II) complexes as antimicrobial, anti-cancer, and antioxidant agents with cyanide ions." Canadian Journal of Chemistry 99, no. 9 (2021): 763–72. http://dx.doi.org/10.1139/cjc-2020-0412.

Full text

Abstract:

Kinetics of substitution reaction of three high-spin pyridylmethylene-8-quinolyl iron (II) complexes by CN– ions were studied spectrophotometrically in various ratios of aqueous–methanol binary mixtures at 298 ± 0.2 K. Kinetics of the substitution reaction follow the rate law (k2[CN−][complex]) on applying of the conditions of the pseudo first order reaction. Reactivity of the reaction was investigated in terms of ligand moiety and solvent effects. The rate of the reaction increased as the co-solvent methanol ratio increased. This reactivity trend is predominantly due to increases in the activity coefficient of those hydrophobic complexes in the organic methanol co-solvent, depending upon the hydrophobicity of the substituent groups (R) in the coordinated ligand in the complexes. Reactivity trends of the prepared complexes in the presence of the inserted hydrophobic salts such as tetrabutylammonium bromide (TBAB), tetraethylammonium bromide (TEAB), and tetramethylammonium bromide (TMAB) or hydrophilic salt potassium bromide (KBr) were studied. The observed decrease in the rate constants with increasing salt concentration was due to the cationic character of the reacting complexes. In addition, the synthesized compounds were tested for antimicrobial activity against selected strains of microbes. The results showed that the order of reactivity of the investigated complexes against the selected microbes were as follows: ppaqFe > paaqFe > pmaqFe. In addition, the investigated ligands and their Fe(II) complexes were screened for anticancer activities against several cell lines of cancer. The ppaqFe complex showed the best cytotoxic efficiency against the selected cancer lines (IC50 = 8.75–21.50 µg/µl), whereas the pmaq ligand showed the lowest cytotoxic efficiency (IC50 = 58.25– 72.40). Furthermore, the antioxidant potential of the presented compounds was studied by applying DPPH assays and showed a potential activity compared with standard vitamin C. The excellent antimicrobial and anticancer activities of the investigated Fe(II) chelates compared with literature values are promising and deserve further study.

APA, Harvard, Vancouver, ISO, and other styles

16

Benamrane, Amal, Brian Herry, Veacheslav Vieru, et al. "Ionic Ruthenium and Iron Based Complexes Bearing Silver Containing Anions as a Potent New Class of Anticancer Agents." Journal of Organometallic Chemistry 934 (February 2021): 121659. http://dx.doi.org/10.1016/j.jorganchem.2020.121659.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Icsel, Ceyda, Veysel T. Yilmaz, Şeyma Aydinlik, and Muhittin Aygun. "New manganese(II), iron(II), cobalt(II), nickel(II) and copper(II) saccharinate complexes of 2,6-bis(2-benzimidazolyl)pyridine as potential anticancer agents." European Journal of Medicinal Chemistry 202 (September 2020): 112535. http://dx.doi.org/10.1016/j.ejmech.2020.112535.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

El-Lateef, Hany, Mai Khalaf, Mohamed Shehata, and Ahmed Abu-Dief. "Fabrication, DFT Calculation, and Molecular Docking of Two Fe(III) Imine Chelates as Anti-COVID-19 and Pharmaceutical Drug Candidate." International Journal of Molecular Sciences 23, no. 7 (2022): 3994. http://dx.doi.org/10.3390/ijms23073994.

Full text

Abstract:

Two tetradentate dibasic chelating Schiff base iron (III) chelates were prepared from the reaction of 2,2′-((1E,1′E)-(1,2-phenylenebis(azanylylidene))bis(methanylylidene))bis(4-bromophenol) (PDBS) and 2,2′-((1E,1′E)-((4-chloro-1,2-phenylene)bis(azanylylidene))-bis(methanylylidene))bis(4-bromophenol) (CPBS) with Fe3+ ions. The prepared complexes were fully characterized with spectral and physicochemical tools such as IR, NMR, CHN analysis, TGA, UV-visible spectra, and magnetic moment measurements. Moreover, geometry optimizations for the synthesized ligands and complexes were conducted using the Gaussian09 program through the DFT approach, to find the best structures and key parameters. The prepared compounds were tested as antimicrobial agents against selected strains of bacteria and fungi. The results suggests that the CPBSFe complex has the highest activity, which is close to the reference. An MTT assay was used to screen the newly synthesized compounds against a variety of cell lines, including colon cancer cells, hepatic cellular carcinoma cells, and breast carcinoma cells. The results are expressed by IC50 value, in which the 48 µg/mL value of the CPBSFe complex indicates its success as a potential anticancer agent. The antioxidant behavior of the two imine chelates was studied by DPPH assay. All the tested imine complexes show potent antioxidant activity compared to the standard Vitamin C. Furthermore, the in vitro assay and the mechanism of binding and interaction efficiency of the tested samples with the receptor of COVID-19 core protease viral protein (PDB ID: 6lu7) and the receptor of Gram-negative bacteria (Escherichia coli, PDB ID: 1fj4) were investigated using molecular docking experiments.

APA, Harvard, Vancouver, ISO, and other styles

19

Chekhun, V. F., A. Mokhir, S. Daum, et al. "PHARMACOLOGICAL EFFECT OF AMINOFERROCENE IN MICE WITH L1210 LEUKEMIA." Experimental Oncology 37, no. 2 (2015): 120–25. http://dx.doi.org/10.31768/2312-8852.2015.37(2):120-125.

Full text

Abstract:

Aim: To study the cytostatic and some biological effects of aminoferrocene using mice with L1210 lymphoid leukemia. Materials and Methods: Experiments were performed on BDF1 male mice (DBA/2, female × C57Bl/6, male) with transplantable L1210 lymphoid leukemia. Determination of antitumor activity of Benzyl-Fc Boron (Bn), it was injected intraperitoneally 6 times daily, starting on day 2 after L1210 leukemia cell transplantation. Doses of Bn such as 26; 260 and 2600 μg/kg were used. The determination of intracellular content of cardiolipin, thiols, reactive oxygen species (ROS) and also analysis of Annexin V positivity and mitochondrial transmembrane potential (JC-1 staining) were performed with use of flow cytometry. The levels of “free iron” complexes, transferrin active forms and the rate of NO generation were measured by EPR-specroscopy. Results: Six daily injections of Bn at a dose of 26 μg/kg resulted in an increased survival of mice with L1210 leukemia by 28% (p < 0.05). Bn led to an increase of apoptotic cells number and ROS amount in leukemia cells. Besides, Bn caused a decrease of cardiolipin and nonprotein thiol compounds content. The membrane electrochemical potential of cell mitochondria was decreased also after Bn administration. Studies using EPR-spectroscopy revealed a significant increase in a level of “free iron”, content of transferrin active species and generation rate of NO by inducible NO-synthase in L1210 cells after aminoferrocene administration. Conclusion: Our data indicate that Benzyl-Fc Boron can be promising candidate for realizing a new strategy of anticancer therapy with the use of ROS-inducing agents.

APA, Harvard, Vancouver, ISO, and other styles

20

Kostova, Irena. "Platinum Complexes as Anticancer Agents." Recent Patents on Anti-Cancer Drug Discovery 1, no. 1 (2006): 1–22. http://dx.doi.org/10.2174/157489206775246458.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Marzano, Cristina, Maura Pellei, Francesco Tisato, and Carlo Santini. "Copper Complexes as Anticancer Agents." Anti-Cancer Agents in Medicinal Chemistry 9, no. 2 (2009): 185–211. http://dx.doi.org/10.2174/187152009787313837.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kostova, Irena. "Ruthenium Complexes as Anticancer Agents." Current Medicinal Chemistry 13, no. 9 (2006): 1085–107. http://dx.doi.org/10.2174/092986706776360941.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Süss-Fink, Georg. "Areneruthenium complexes as anticancer agents." Dalton Trans. 39, no. 7 (2010): 1673–88. http://dx.doi.org/10.1039/b916860p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Collins, Martin, David Ewing, Grahame Mackenzie, et al. "Metal complexes as anticancer agents." Inorganic Chemistry Communications 3, no. 9 (2000): 453–57. http://dx.doi.org/10.1016/s1387-7003(00)00108-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Jin, Suxing, Yan Guo, Zijian Guo, and Xiaoyong Wang. "Monofunctional Platinum(II) Anticancer Agents." Pharmaceuticals 14, no. 2 (2021): 133. http://dx.doi.org/10.3390/ph14020133.

Full text

Abstract:

Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]+ (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

26

Kolesnik, D. L., O. N. Pyaskovskaya, I. V. Boychuk, et al. "EFFECT OF DICHLOROACETATE ON LEWIS LUNG CARCINOMA GROWTH AND METASTASIS." Experimental Oncology 37, no. 2 (2015): 126–29. http://dx.doi.org/10.31768/2312-8852.2015.37(2):126-129.

Full text

Abstract:

A hallmark of malignancy is excessive tumor glycolysis, even in the presence of oxygen, which causes lactacidosis in the tumor microenvironment and favors tumor cell proliferation and survival. For this reason antimetabolic agents which target tumor cell metabolism are being researched extensively as promising anticancer drugs. Aim: To study the effect of lactacidosis on survival of Lewis lung carcinoma (LLC) cells at the conditions of nutritional substrate deficiency in vitro and evaluate antitumor and antimetastatic activity against LLC/ R9 in vivo. Materials and Methods: LLC variant LLC/R9 was used as experimental tumor model. Tumor cell viability was determined using trypan blue staining. Apoptosis level was counted with the use of Hoechst 33258 dye. Lactate content in the tumor tissue was evaluated by enzyme method with the use of lactate dehydrogenase. Reactive oxygen species was determined using 2.7-dichlorofluorescein diacetate. Effects of dichloroacetate (DCA) on the growth and metastasis of LLC/R9 were analyzed by routine procedures. Evaluation of DCA effect toward electron-transport chain (ETC) components was performed using EPR. Results: It has been shown that at the conditions of lactacidosis and glucose deficiency, LLC/R9 cell viability in vitro was higher by 30% (р < 0.05) and apoptosis level was triply lower (р < 0.05) than these indices at the conditions of glucose deficiency only. In mice with transplanted LLC/R9 tumors treated for 3 weeks per os with DCA at the total dose of 1.5 g/kg of body weight starting from the next day after tumor transplantation, the primary tumor volume was just by 30% lower than that in control group. At the same time, the number and volume of lung metastases in animals treated with DCA were by 59% (р < 0.05) and 94% (р < 0.05) lower, respectively, than these indices in the control group. DCA treatment resulted in nearly 30% increase (р < 0.05) of lactate content in tumor tissue compared to that in the control, but did not affect significantly the levels of heme iron complexes with NO (at gmed = 2.007) in mitochondrial ETC proteins and Fe-S cluster proteins (at g = 1.94) in tumor cells. Conclusions: It has been shown that lactacidosis significantly promoted LLC/R9 cell survival at the conditions of glucose deficiency in vitro. If LLC/R9 developed in vivo, DCA as the compound with antilactacidosis activity did not suppress significantly the primary tumor growth but exerted significant antimetastatic activity.

APA, Harvard, Vancouver, ISO, and other styles

27

Kostova, Irena, and Bentham Science Publisher Bentham Science Publishers. "Gold Coordination Complexes as Anticancer Agents." Anti-Cancer Agents in Medicinal Chemistry 6, no. 1 (2006): 19–32. http://dx.doi.org/10.2174/187152006774755500.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Pellei, Maura, Fabio Del Bello, Marina Porchia, and Carlo Santini. "Zinc coordination complexes as anticancer agents." Coordination Chemistry Reviews 445 (October 2021): 214088. http://dx.doi.org/10.1016/j.ccr.2021.214088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Liu, Zhe, and Peter J. Sadler. "Organoiridium Complexes: Anticancer Agents and Catalysts." Accounts of Chemical Research 47, no. 4 (2014): 1174–85. http://dx.doi.org/10.1021/ar400266c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Munteanu, Catherine R., and Kogularamanan Suntharalingam. "Advances in cobalt complexes as anticancer agents." Dalton Transactions 44, no. 31 (2015): 13796–808. http://dx.doi.org/10.1039/c5dt02101d.

Full text

Abstract:

This perspective describes the advances in cobalt-containing compounds as anticancer agents. Cobalt, being an essential trace element, offers a less toxic alternative to traditional platinum-based anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

31

Kostova, Irena. "Titanium and Vanadium Complexes as Anticancer Agents." Anti-Cancer Agents in Medicinal Chemistry 9, no. 8 (2009): 827–42. http://dx.doi.org/10.2174/187152009789124646.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Chundawat, Narendra Singh, Sapana Jadoun, Payam Zarrintaj, and Narendra Pal Singh Chauhan. "Lanthanide complexes as anticancer agents: A review." Polyhedron 207 (October 2021): 115387. http://dx.doi.org/10.1016/j.poly.2021.115387.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Gorle, Anil K., Alaina J. Ammit, Lynne Wallace, F. Richard Keene, and J. Grant Collins. "Multinuclear ruthenium(ii) complexes as anticancer agents." New J. Chem. 38, no. 9 (2014): 4049–59. http://dx.doi.org/10.1039/c4nj00545g.

Full text

Abstract:

The dinuclear ruthenium complex with X = H is four-times more cytotoxic than cisplatin against breast cancer cell lines; however, when X = NO<sub>2</sub> the ruthenium complex is less active than cisplatin.

APA, Harvard, Vancouver, ISO, and other styles

34

LIU, HongKe, Qing YANG, JinTao WANG, and WenPing LUO. "Organometallic Ru(Ⅱ) complexes as anticancer agents." SCIENTIA SINICA Chimica 44, no. 4 (2014): 437–47. http://dx.doi.org/10.1360/032013-332.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Santini, Carlo, Maura Pellei, Valentina Gandin, Marina Porchia, Francesco Tisato, and Cristina Marzano. "Advances in Copper Complexes as Anticancer Agents." Chemical Reviews 114, no. 1 (2013): 815–62. http://dx.doi.org/10.1021/cr400135x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Sridevi, G., S. Arul Antony, and R. Angayarkani. "Schiff Base Metal Complexes as Anticancer Agents." Asian Journal of Chemistry 31, no. 3 (2019): 493–504. http://dx.doi.org/10.14233/ajchem.2019.21697.

Full text

Abstract:

Cutting-edge practices in bioinorganic chemistry are pivotal for enhancing the layout of compounds to lessen poisonous facet effect and recognize their mechanism of action. A powerful anticancer agent should own inherent, inhibitory property and also delivery, dosage and residence time in vivo. Organic function and conformation of mutated gene may be altered by way of binding of metal ions. Upswing of activities counting on the structural data, intending in enhancing and growing different forms of metal based compounds, continuous seek of extra metal based compounds have been synthesized via revamping the prevailing chemical shape via ligand substitution. The prevailing paper addresses the trendy development in the design of novel antitumor agents primarily based on transition metal complex via highlighting the near dating among their structural alternatives and cytotoxic ability.

APA, Harvard, Vancouver, ISO, and other styles

37

Kaur, Harmeet, Snehlata Yadav, and Balasubramanian Narasimhan. "Diazenyl Derivatives and their Complexes as Anticancer Agents." Anti-Cancer Agents in Medicinal Chemistry 16, no. 10 (2016): 1240–65. http://dx.doi.org/10.2174/1871520616666160607012042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Paprocka, Renata, Małgorzata Wiese-Szadkowska, Sabina Janciauskiene, Tomasz Kosmalski, Marcelina Kulik, and Anna Helmin-Basa. "Latest developments in metal complexes as anticancer agents." Coordination Chemistry Reviews 452 (February 2022): 214307. http://dx.doi.org/10.1016/j.ccr.2021.214307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Lenis-Rojas, Oscar A., Beatriz Carvalho, Rui Cabral, et al. "Manganese(I) tricarbonyl complexes as potential anticancer agents." JBIC Journal of Biological Inorganic Chemistry 27, no. 1 (2021): 49–64. http://dx.doi.org/10.1007/s00775-021-01910-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Kaplanis, M., I. Roupa, B. Mavroidi, et al. "Rhenium(I) DNA-intercalating complexes as anticancer agents." Nuclear Medicine and Biology 72-73 (July 2019): S24. http://dx.doi.org/10.1016/s0969-8051(19)30255-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Pratesi, Alessandro, Damiano Cirri, Mirjana D. Đurović, et al. "New gold carbene complexes as candidate anticancer agents." BioMetals 29, no. 5 (2016): 905–11. http://dx.doi.org/10.1007/s10534-016-9962-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Canil, Giovanni, Simona Braccini, Tiziano Marzo, et al. "Photocytotoxic Pt(iv) complexes as prospective anticancer agents." Dalton Transactions 48, no. 29 (2019): 10933–44. http://dx.doi.org/10.1039/c9dt01645g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Liu, Zhe, and Peter J. Sadler. "ChemInform Abstract: Organoiridium Complexes: Anticancer Agents and Catalysts." ChemInform 45, no. 25 (2014): no. http://dx.doi.org/10.1002/chin.201425246.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Andrade, Marta A., and Luísa M. D. R. S. Martins. "Novel Chemotherapeutic Agents - The Contribution of Scorpionates." Current Medicinal Chemistry 26, no. 41 (2020): 7452–75. http://dx.doi.org/10.2174/0929867325666180914104237.

Full text

Abstract:

: The development of safe and effective chemotherapeutic agents is one of the uppermost priorities and challenges of medicinal chemistry and new transition metal complexes are being continuously designed and tested as anticancer agents. Scorpionate ligands have played a great role in coordination chemistry, since their discovery by Trofimenko in the late 1960s, with significant contributions in the fields of catalysis and bioinorganic chemistry. Scorpionate metal complexes have also shown interesting anticancer properties, and herein, the most recent (last decade) and relevant scorpionate complexes reported for application in medicinal chemistry as chemotherapeutic agents are reviewed. The current progress on the anticancer properties of transition metal complexes bearing homo- or hetero- scorpionate ligands, derived from bis- or tris-(pyrazol-1-yl)-borate or -methane moieties is highlighted.

APA, Harvard, Vancouver, ISO, and other styles

45

Wang, Chuanlan, Jinfeng Liu, Zhenzhen Tian, et al. "Half-sandwich iridium N-heterocyclic carbene anticancer complexes." Dalton Transactions 46, no. 21 (2017): 6870–83. http://dx.doi.org/10.1039/c7dt00575j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Ma, Dik-Lung, Chun Wu, Ke-Jia Wu, and Chung-Hang Leung. "Iridium(III) Complexes Targeting Apoptotic Cell Death in Cancer Cells." Molecules 24, no. 15 (2019): 2739. http://dx.doi.org/10.3390/molecules24152739.

Full text

Abstract:

Targeting apoptosis is a principal strategy in the design of anticancer drugs. In recent years, non-platinum-based scaffolds have been exploited as viable candidates for the exploitation of anticancer agents with potentially lower toxicity than the widely used cisplatin analogues. This review highlights the latest advances in developing iridium(III) complexes as anticancer agents that act particularly via targeting apoptotic cell death in cancer cells.

APA, Harvard, Vancouver, ISO, and other styles

47

Jain, Tapan K., Marco A. Morales, Sanjeeb K. Sahoo, Diandra L. Leslie-Pelecky, and Vinod Labhasetwar. "Iron Oxide Nanoparticles for Sustained Delivery of Anticancer Agents." Molecular Pharmaceutics 2, no. 3 (2005): 194–205. http://dx.doi.org/10.1021/mp0500014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Kostova, Irena. "Retraction Notice: Titanium and Vanadium Complexes as Anticancer Agents." Anti-Cancer Agents in Medicinal Chemistry 21, no. 9 (2021): 1200. http://dx.doi.org/10.2174/187152062109210506092457.

Full text

Abstract:

<p>The article entitled “Titanium and vanadium complexes as anticancer agents”, by Kostova I., has been retracted. Kindly see Bentham Science Policy on Article retraction at the link given below: <p> (https://benthamscience.com/journals/anti-cancer-agents-in-medicinal-chemistry/author-guidelines/). This article has been retracted on the request of the Editor. <p> The authors have plagiarized a paper that had already been published in the journal Current Medicinal Chemistry, 2000, 7(12), 1289-1303. https://www.eurekaselect.com/65771/article. <p> It is a pre-requisite for authors to declare explicitly that their work is original and has not been published elsewhere. Authors are advised to properly cite the original source to avoid plagiarism and copyright violation. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause. <p> The Bentham Editorial Policy on Article Retraction can be found at https://benthamscience.com/editorial-policiesmain. php. <p> Bentham Science Disclaimer <p> It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

APA, Harvard, Vancouver, ISO, and other styles

49

Zhou, Cheng-He, Yi-Yi Zhang, Cong-Yan Yan, Kun Wan, Lin-Ling Gan, and Yuan Shi. "Recent Researches in Metal Supramolecular Complexes as Anticancer Agents." Anti-Cancer Agents in Medicinal Chemistry 10, no. 5 (2010): 371–95. http://dx.doi.org/10.2174/1871520611009050371.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Hartinger, Christian, Alexey Nazarov, Shaheen Ashraf, Paul Dyson, and Bernhard Keppler. "Carbohydrate-Metal Complexes and their Potential as Anticancer Agents." Current Medicinal Chemistry 15, no. 25 (2008): 2574–91. http://dx.doi.org/10.2174/092986708785908978.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!